GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Innophos Holdings Inc (NAS:IPHS) » Definitions » EBITDA per Share

Innophos Holdings (Innophos Holdings) EBITDA per Share

: $5.05 (TTM As of Sep. 2019)
View and export this data going back to 2006. Start your Free Trial

Innophos Holdings's EBITDA per Share for the three months ended in Sep. 2019 was $1.23. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $5.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Innophos Holdings's EBITDA per Share or its related term are showing as below:

IPHS's 3-Year EBITDA Growth Rate is not ranked *
in the Chemicals industry.
Industry Median: 8.9
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Innophos Holdings's EBITDA for the three months ended in Sep. 2019 was $24.4 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Innophos Holdings EBITDA per Share Historical Data

The historical data trend for Innophos Holdings's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innophos Holdings Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EBITDA per Share
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.18 4.21 5.87 5.26 5.13

Innophos Holdings Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EBITDA per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.30 1.19 1.31 1.32 1.23

Innophos Holdings EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Innophos Holdings's EBITDA per Share for the fiscal year that ended in Dec. 2018 is calculated as

EBITDA per Share(A: Dec. 2018 )
=EBITDA/Shares Outstanding (Diluted Average)
=101.331/19.760
=5.13

Innophos Holdings's EBITDA per Share for the quarter that ended in Sep. 2019 is calculated as

EBITDA per Share(Q: Sep. 2019 )
=EBITDA/Shares Outstanding (Diluted Average)
=24.367/19.785
=1.23

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innophos Holdings  (NAS:IPHS) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Innophos Holdings EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Innophos Holdings's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Innophos Holdings (Innophos Holdings) Business Description

Traded in Other Exchanges
N/A
Address
259 Prospect Plains Road, Cranbury, NJ, USA, 08512
Innophos Holdings Inc is a holding company that manufactures and sells through its subsidiaries a variety of ingredients used in the production of food, beverages, dietary supplements, pharmaceuticals, and oral care products. Innophos ingredients are made primarily from specialty phosphates. The company organizes itself into three segments namely Food, Health and Nutrition; Industrial Specialties and Other. The Food, Health and Nutrition segment contribute the maximum revenue. The company operates in U.S., Canada, Mexico and other countries.
Executives
John M Steitz director ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
Kim Ann Mink director, officer: Chairman, CEO, President 259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
Gary A Cappeline director 50 E RIVERCENTER BLVD, COVINGTON KY 41012
Karen R Osar director C/O WESTVACO CORP, ONE HIGH RIDGE PARK, STAMFORD CT 06905
Mark Santangelo officer: Sr. VP, Mfg, Eng & EH&S 15710 JOHN F. KENNEDY BLVD., SUITE 300 HOUSTON TX 77032
Peter T Thomas director 1000 LAKESIDE AVENUE, CLEVELAND OH 44114
Hermanus Kieftenbeld officer: Senior VP and CFO 259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
James P. Zallie director 5 WESTBROOK CORPORATE CENTER, WESTCHESTER IL 60154
Randy Gress director, officer: CEO 259 PROSPECT PLAINS ROAD, P O BOX 8000, CRANBURY NJ 08512-8000
Stephen M Zide director BAIN CAPITAL PARTNERS, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Richard Heyse officer: VP-Chief Financial Officer 259 PROSPECT PLAINS ROAD, BUILDING G, P O BOX 8000, CRANBURY NJ 08512-8000
Bain Capital Investors Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Partners Vii Lp 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Llc 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Lp 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116

Innophos Holdings (Innophos Holdings) Headlines